Cinnamon drugs for diabetes
This article was originally published in The Tan Sheet
Executive Summary
PhytoMedical Technologies plans to fast-track development of a new drug class of cinnamon-derived polyphenolic compounds that could be used to treat type-2 diabetes, the firm announces Dec. 6. The compounds "possess unique antioxidant and insulin enhancing qualities" distinct from existing classes of diabetes drugs, the Princeton, N.J.-based firm states. According to results from a study of patients with type-2 diabetes, the compounds reduced levels of blood sugar by an average of 18% to 29%, triglycerides by 23% to 30%, LDL cholesterol by 7% to 27% and overall cholesterol by 12% to 26% without side effects, the company says. PhytoMedical plans to end its initial research and development work at the beginning of February and begin drug development in order to quickly pursue its investigational new drug (IND) application with FDA, according to company President & CEO Greg Wujek. The firm plans to begin Phase I human trials as soon as FDA approves the IND, according to the company...
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.